Loading...

PerkinElmer

NYSE:PKI
Snowflake Description

Acceptable track record with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
PKI
NYSE
$11B
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The last earnings update was 71 days ago. More info.


Add to Portfolio Compare Print
PKI Share Price and Events
7 Day Returns
-0.8%
NYSE:PKI
-5.2%
US Life Sciences
0.6%
US Market
1 Year Returns
23.6%
NYSE:PKI
22.2%
US Life Sciences
4.1%
US Market
PKI Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
PerkinElmer (PKI) -0.8% 1.8% 1% 23.6% 70.9% 99.6%
US Life Sciences -5.2% 0.1% 6.1% 22.2% 81.2% 106.7%
US Market 0.6% 3.8% 2.8% 4.1% 37.3% 42.5%
1 Year Return vs Industry and Market
  • PKI outperformed the Life Sciences industry which returned 22.2% over the past year.
  • PKI outperformed the Market in United States of America which returned 4.1% over the past year.
Price Volatility
PKI
Industry
5yr Volatility vs Market

PKI Value

 Is PerkinElmer undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of PerkinElmer to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for PerkinElmer.

NYSE:PKI Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 10 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 9.4%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NYSE:PKI
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Life Sciences Unlevered Beta Simply Wall St/ S&P Global 1.02
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.022 (1 + (1- 21%) (19.61%))
1.121
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.12
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.121 * 5.96%)
9.41%

Discounted Cash Flow Calculation for NYSE:PKI using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for PerkinElmer is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NYSE:PKI DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 9.41%)
2020 457.61 Analyst x4 418.25
2021 526.62 Analyst x3 439.93
2022 582.67 Est @ 10.64% 444.89
2023 630.85 Est @ 8.27% 440.25
2024 672.54 Est @ 6.61% 428.97
2025 709.15 Est @ 5.44% 413.42
2026 741.98 Est @ 4.63% 395.36
2027 772.11 Est @ 4.06% 376.03
2028 800.37 Est @ 3.66% 356.27
2029 827.44 Est @ 3.38% 336.64
Present value of next 10 years cash flows $4,050.01
NYSE:PKI DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $827.44 × (1 + 2.73%) ÷ (9.41% – 2.73%)
$12,724.85
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $12,724.85 ÷ (1 + 9.41%)10
$5,177.03
NYSE:PKI Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $4,050.01 + $5,177.03
$9,227.04
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $9,227.04 / 110.92
$83.19
NYSE:PKI Discount to Share Price
Calculation Result
Value per share (USD) From above. $83.19
Current discount Discount to share price of $95.10
= -1 x ($95.10 - $83.19) / $83.19
-14.3%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of PerkinElmer is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for PerkinElmer's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are PerkinElmer's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NYSE:PKI PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $2.23
NYSE:PKI Share Price ** NYSE (2019-07-17) in USD $95.1
United States of America Life Sciences Industry PE Ratio Median Figure of 22 Publicly-Listed Life Sciences Companies 39.37x
United States of America Market PE Ratio Median Figure of 3,082 Publicly-Listed Companies 17.98x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of PerkinElmer.

NYSE:PKI PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NYSE:PKI Share Price ÷ EPS (both in USD)

= 95.1 ÷ 2.23

42.61x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • PerkinElmer is overvalued based on earnings compared to the US Life Sciences industry average.
  • PerkinElmer is overvalued based on earnings compared to the United States of America market.
Price based on expected Growth
Does PerkinElmer's expected growth come at a high price?
Raw Data
NYSE:PKI PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 42.61x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 10 Analysts
19.6%per year
United States of America Life Sciences Industry PEG Ratio Median Figure of 20 Publicly-Listed Life Sciences Companies 2.71x
United States of America Market PEG Ratio Median Figure of 2,122 Publicly-Listed Companies 1.59x

*Line of best fit is calculated by linear regression .

NYSE:PKI PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 42.61x ÷ 19.6%

2.17x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • PerkinElmer is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on PerkinElmer's assets?
Raw Data
NYSE:PKI PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $23.79
NYSE:PKI Share Price * NYSE (2019-07-17) in USD $95.1
United States of America Life Sciences Industry PB Ratio Median Figure of 38 Publicly-Listed Life Sciences Companies 4.67x
United States of America Market PB Ratio Median Figure of 5,241 Publicly-Listed Companies 1.81x
NYSE:PKI PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NYSE:PKI Share Price ÷ Book Value per Share (both in USD)

= 95.1 ÷ 23.79

4x

* Primary Listing of PerkinElmer.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • PerkinElmer is good value based on assets compared to the US Life Sciences industry average.
X
Value checks
We assess PerkinElmer's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Life Sciences industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Life Sciences industry average (and greater than 0)? (1 check)
  5. PerkinElmer has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

PKI Future Performance

 How is PerkinElmer expected to perform in the next 1 to 3 years based on estimates from 10 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
19.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is PerkinElmer expected to grow at an attractive rate?
  • PerkinElmer's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • PerkinElmer's earnings growth is expected to exceed the United States of America market average.
  • PerkinElmer's revenue growth is positive but not above the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NYSE:PKI Future Growth Rates Data Sources
Data Point Source Value (per year)
NYSE:PKI Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 10 Analysts 19.6%
NYSE:PKI Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 10 Analysts 6.7%
United States of America Life Sciences Industry Earnings Growth Rate Market Cap Weighted Average 16.1%
United States of America Life Sciences Industry Revenue Growth Rate Market Cap Weighted Average 7.1%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14.1%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NYSE:PKI Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 10 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NYSE:PKI Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 3,335 616 463 4
2020-12-31 3,134 544 411 8
2019-12-31 2,925 468 332 8
NYSE:PKI Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 2,783 320 247
2018-12-30 2,778 311 237
2018-09-30 2,663 280 128
2018-07-01 2,543 245 149
2018-04-01 2,387 220 147
2017-12-31 2,257 288 157
2017-10-01 2,182 309 258
2017-07-02 2,142 324 215
2017-04-02 2,132 372 210
2017-01-01 2,116 351 216
2016-10-02 1,999 327 198
2016-07-03 2,048 314 199
2016-04-03 2,076 281 190

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • PerkinElmer's earnings are expected to grow by 19.6% yearly, however this is not considered high growth (20% yearly).
  • PerkinElmer's revenue is expected to grow by 6.7% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NYSE:PKI Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 10 Analyst Estimates (S&P Global) See Below

All data from PerkinElmer Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NYSE:PKI Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 4.10 4.41 3.72 3.00
2020-12-31 3.73 4.03 3.25 5.00
2019-12-31 3.06 3.40 2.77 5.00
NYSE:PKI Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 2.23
2018-12-30 2.15
2018-09-30 1.16
2018-07-01 1.35
2018-04-01 1.33
2017-12-31 1.43
2017-10-01 2.35
2017-07-02 1.96
2017-04-02 1.92
2017-01-01 1.97
2016-10-02 1.80
2016-07-03 1.79
2016-04-03 1.70

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • PerkinElmer is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess PerkinElmer's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
PerkinElmer has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

PKI Past Performance

  How has PerkinElmer performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare PerkinElmer's growth in the last year to its industry (Life Sciences).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • PerkinElmer's year on year earnings growth rate has been positive over the past 5 years.
  • PerkinElmer's 1-year earnings growth exceeds its 5-year average (68% vs 2.4%)
  • PerkinElmer's earnings growth has exceeded the US Life Sciences industry average in the past year (68% vs 45.3%).
Earnings and Revenue History
PerkinElmer's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from PerkinElmer Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NYSE:PKI Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 2,782.76 246.89 789.52 195.99
2018-12-30 2,778.00 237.48 787.47 194.00
2018-09-30 2,663.28 127.71 761.44 179.76
2018-07-01 2,543.24 148.81 718.54 165.80
2018-04-01 2,386.84 146.86 667.07 152.16
2017-12-31 2,256.98 156.89 620.46 139.46
2017-10-01 2,182.12 257.62 586.67 134.66
2017-07-02 2,142.34 214.99 580.20 129.29
2017-04-02 2,131.62 210.02 584.28 127.59
2017-01-01 2,115.52 215.71 584.59 124.18
2016-10-02 1,999.33 198.00 573.66 107.99
2016-07-03 2,048.27 198.98 582.77 109.58
2016-04-03 2,075.94 190.22 582.84 110.39
2016-01-03 2,104.82 188.79 585.70 112.54
2015-10-04 2,262.63 175.52 661.39 126.86
2015-06-28 2,241.25 163.52 656.83 126.21
2015-03-29 2,233.51 166.53 655.59 123.88
2014-12-28 2,069.88 130.14 647.87 108.06
2014-09-28 2,220.70 203.31 576.24 122.96
2014-06-29 2,200.75 201.17 576.84 123.73
2014-03-30 2,185.25 176.44 579.27 127.78
2013-12-29 2,157.59 174.27 580.85 132.40
2013-09-29 2,138.64 84.62 622.26 133.15
2013-06-30 2,126.14 72.85 626.67 134.35
2013-03-31 2,107.26 79.14 627.90 134.01
2012-12-30 2,105.19 71.29 627.92 131.84
2012-09-30 2,081.61 1.41 668.18 130.60

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • PerkinElmer has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • PerkinElmer used its assets less efficiently than the US Life Sciences industry average last year based on Return on Assets.
  • PerkinElmer's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess PerkinElmer's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Life Sciences industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
PerkinElmer has a total score of 3/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

PKI Health

 How is PerkinElmer's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up PerkinElmer's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • PerkinElmer is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • PerkinElmer's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of PerkinElmer's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are 0.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from PerkinElmer Company Filings, last reported 3 months ago.

NYSE:PKI Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 2,638.47 1,862.27 134.25
2018-12-30 2,584.96 1,856.96 163.11
2018-09-30 2,572.47 1,867.67 149.51
2018-07-01 2,517.18 1,965.97 163.39
2018-04-01 2,555.25 2,041.85 180.80
2017-12-31 2,503.19 1,970.21 202.13
2017-10-01 2,536.03 1,074.37 709.49
2017-07-02 2,438.64 1,055.12 616.31
2017-04-02 2,208.99 1,018.06 288.33
2017-01-01 2,153.57 1,009.35 359.27
2016-10-02 2,135.42 1,095.69 311.66
2016-07-03 2,088.20 1,020.43 248.08
2016-04-03 2,049.48 1,083.03 210.73
2016-01-03 2,110.44 974.66 237.93
2015-10-04 2,054.32 989.87 195.07
2015-06-28 2,120.90 949.73 192.17
2015-03-29 2,059.89 976.77 168.92
2014-12-28 2,042.10 1,007.19 174.82
2014-09-28 2,062.75 820.08 203.68
2014-06-29 2,055.99 855.58 205.26
2014-03-30 2,029.44 889.50 224.11
2013-12-29 1,994.49 894.40 173.24
2013-09-29 1,919.57 895.41 132.30
2013-06-30 1,859.85 963.27 112.47
2013-03-31 1,834.42 988.65 125.87
2012-12-30 1,939.81 940.60 171.44
2012-09-30 1,942.44 932.33 170.83
  • PerkinElmer's level of debt (70.6%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (45.8% vs 70.6% today).
  • Debt is not well covered by operating cash flow (17.2%, less than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 6x coverage).
X
Financial health checks
We assess PerkinElmer's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. PerkinElmer has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

PKI Dividends

 What is PerkinElmer's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0.29%
Current annual income from PerkinElmer dividends. Estimated to be 0.29% next year.
If you bought $2,000 of PerkinElmer shares you are expected to receive $6 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • PerkinElmer's pays a lower dividend yield than the bottom 25% of dividend payers in United States of America (1.43%).
  • PerkinElmer's dividend is below the markets top 25% of dividend payers in United States of America (3.72%).
Upcoming dividend payment

Purchase PerkinElmer before the 'Buy Limit' to receive their next dividend payment.

Dividends are usually paid every 3 or 6 months, you can time your share purchase to take advantage of upcoming dividend payments.
Dividend payment calendar
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NYSE:PKI Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 10 Analyst Estimates (S&P Global) See Below
United States of America Life Sciences Industry Average Dividend Yield Market Cap Weighted Average of 7 Stocks 0.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2017 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NYSE:PKI Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2021-12-31 0.28 6.00
2020-12-31 0.28 8.00
2019-12-31 0.28 8.00
NYSE:PKI Past Annualized Dividends Data
Date (Data in $) Dividend per share (annual) Avg. Yield (%)
2019-04-25 0.280 0.303
2019-01-24 0.280 0.297
2018-10-24 0.280 0.341
2018-07-23 0.280 0.316
2018-04-26 0.280 0.372
2018-01-26 0.280 0.368
2017-10-27 0.280 0.379
2017-07-24 0.280 0.413
2017-04-28 0.280 0.431
2017-01-27 0.280 0.500
2016-10-26 0.280 0.539
2016-07-27 0.280 0.516
2016-04-25 0.280 0.523
2016-01-28 0.280 0.583
2015-10-29 0.280 0.547
2015-07-23 0.280 0.575
2015-04-27 0.280 0.535
2015-01-23 0.280 0.581
2014-10-23 0.280 0.643
2014-07-24 0.280 0.636
2014-04-22 0.280 0.617
2014-01-24 0.280 0.630
2013-10-24 0.280 0.710
2013-07-26 0.280 0.758
2013-06-13 0.280 0.839
2013-01-25 0.280 0.838
2012-10-24 0.280 0.879
2012-07-27 0.280 0.988
2012-06-27 0.280 1.122
2012-01-30 0.280 1.057
2011-12-16 0.280 1.314
2011-07-25 0.280 1.387
2011-06-14 0.280 1.057
2011-01-24 0.280 1.044
2010-10-27 0.280 1.132
2010-07-30 0.280 1.263
2010-06-03 0.280 1.354
2010-01-25 0.280 1.227
2009-10-21 0.280 1.406
2009-06-12 0.280 1.542
2009-01-28 0.280 1.999
2008-10-22 0.280 1.805
2008-07-23 0.280 1.077

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • PerkinElmer is not paying a notable dividend for United States of America, therefore no need to check if the payments are stable.
  • PerkinElmer is not paying a notable dividend for United States of America, therefore no need to check if the payments are increasing.
Current Payout to shareholders
What portion of PerkinElmer's earnings are paid to the shareholders as a dividend.
  • No need to calculate the sustainability of PerkinElmer's dividends as it is not paying a notable one for United States of America.
Future Payout to shareholders
  • No need to calculate the sustainability of PerkinElmer's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess PerkinElmer's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can PerkinElmer afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. PerkinElmer has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

PKI Management

 What is the CEO of PerkinElmer's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Rob Friel
COMPENSATION $13,961,376
AGE 63
TENURE AS CEO 11.4 years
CEO Bio

Mr. Robert F. Friel, also known as Rob, has been the Chairman of PerkinElmer Inc. since April 29, 2009 and also its Executive Director since January 1, 2006. He has been the Chairman of PerkinElmer LAS (Germany) GmbH since April 2009 and also has been its Chief Executive Officer and President since February 2008 and August 2007 respectively. Mr. Friel has been the Chief Executive Officer of PerkinElmer, Inc. since February 2008 and August 1, 2007 respectively. He served as President of PerkinElmer, Inc. since August 1, 2007 to January 1, 2019. He served as the Chief Operating Officer of PerkinElmer from August 1, 2007 to February 2008, Chief Financial Officer from February 1999 to January 1, 2006, Executive Vice President from October 2004 to January 1, 2006 and Senior Vice President from February 1999 to January 2006. From 1997 to 1999, he served as the Corporate Vice President and Treasurer of AlliedSignal Inc. He served as the President of Life and Analytical Sciences, a unit of PerkinElmer from January 2006 to August 2007. He served as a Vice President of Finance and Administration of AlliedSgnal Engines from 1992 to 1996. He joined PerkinElmer in 1999. He served for Nineteen years for Allied Signal Inc. (now Honeywell International), progressing through a series of financial management positions and served as its Corporate Treasurer. He started his career at Franklin Mint Corp. He served as Vice Chairman of Life and Analytical Sciences unit since January 2006. He serves as a Director of Fairchild Semiconductor Corp. He has been a Director of Analytical and Life Science Systems Association since January 1, 2006, NuVasive, Inc. since February 2016. He has been an Independent Director of Xylem Inc. since December 13, 2012. He has been Director of New York Life Insurance Company since January 1, 2019. He serves on the Board of March of Dimes Foundation. He served as an Independent Director of CareFusion Corporation from June 9, 2009 to March 17, 2015. He served as a Director of Millennium Pharmaceuticals, Inc. since June 15, 2005 and Fairchild Semiconductor International Inc., from March 31, 2004 to May 6, 2009. Mr. Friel holds a Bachelor of Arts degree in Economics from Lafayette College and a Master of Science degree in Taxation from Farleigh Dickinson University.

CEO Compensation
  • Rob's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Rob's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the PerkinElmer management team in years:

3.3
Average Tenure
50.5
Average Age
  • The tenure for the PerkinElmer management team is about average.
Management Team

Rob Friel

TITLE
Chairman & CEO
COMPENSATION
$14M
AGE
63
TENURE
11.4 yrs

Prahlad Singh

TITLE
President & COO
COMPENSATION
$2M
AGE
54
TENURE
0.5 yrs

Jamey Mock

TITLE
Senior VP & CFO
COMPENSATION
$4M
AGE
42
TENURE
1.2 yrs

Joel Goldberg

TITLE
Senior VP of Administration
COMPENSATION
$3M
AGE
50
TENURE
11 yrs

Andrew Okun

TITLE
VP & Chief Accounting Officer
AGE
49
TENURE
8.3 yrs

Bryan Kipp

TITLE
Vice President of Investor Relations

Deborah Butters

TITLE
Senior VP & Chief Human Resources Officer
AGE
49
TENURE
3 yrs

Daniel Tereau

TITLE
Senior Vice President of Strategy & Business Development
AGE
51
TENURE
3.5 yrs

Tajinder Vohra

TITLE
Senior Vice President of Global Operations
AGE
53
TENURE
1.4 yrs

Dave Francisco

TITLE
CFO of Human Health & Corporate Treasurer
Board of Directors Tenure

Average tenure and age of the PerkinElmer board of directors in years:

4.4
Average Tenure
62
Average Age
  • The tenure for the PerkinElmer board of directors is about average.
Board of Directors

Rob Friel

TITLE
Chairman & CEO
COMPENSATION
$14M
AGE
63
TENURE
10.3 yrs

Alexis Michas

TITLE
Lead Director
COMPENSATION
$337K
AGE
61

Pat Sullivan

TITLE
Independent Director
COMPENSATION
$269K
AGE
67
TENURE
11.4 yrs

Peter Barrett

TITLE
Independent Director
COMPENSATION
$276K
AGE
66
TENURE
7.4 yrs

Sam Chapin

TITLE
Independent Director
COMPENSATION
$290K
AGE
61
TENURE
2.8 yrs

Frank Witney

TITLE
Independent Director
COMPENSATION
$265K
AGE
65
TENURE
3 yrs

Sylvie Grégoire

TITLE
Independent Director
COMPENSATION
$265K
AGE
58
TENURE
4.4 yrs

Pascale Witz

TITLE
Director
COMPENSATION
$265K
AGE
52
TENURE
1.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
07. Feb 19 Sell Nicholas Lopardo Individual 05. Feb 19 05. Feb 19 -1,600 $92.67 $-148,274
04. Dec 18 Sell Alexis Michas Individual 03. Dec 18 03. Dec 18 -5,000 $90.95 $-454,750
03. Dec 18 Sell Nicholas Lopardo Individual 30. Nov 18 30. Nov 18 -2,000 $87.08 $-174,160
14. Nov 18 Sell Patrick Sullivan Individual 13. Nov 18 13. Nov 18 -10,000 $81.64 $-816,400
07. Nov 18 Sell Pascale Witz Individual 06. Nov 18 06. Nov 18 -2,206 $83.62 $-184,455
06. Nov 18 Sell Nicholas Lopardo Individual 05. Nov 18 05. Nov 18 -2,000 $82.12 $-164,244
04. Sep 18 Sell Nicholas Lopardo Individual 31. Aug 18 31. Aug 18 -2,700 $92.28 $-249,156
29. Aug 18 Sell Nicholas Lopardo Individual 28. Aug 18 28. Aug 18 -3,500 $89.40 $-312,900
07. Aug 18 Sell Nicholas Lopardo Individual 06. Aug 18 06. Aug 18 -3,505 $85.60 $-300,028
X
Management checks
We assess PerkinElmer's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. PerkinElmer has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

PKI News

Simply Wall St News

Should You Be Tempted To Sell PerkinElmer, Inc. (NYSE:PKI) Because Of Its P/E Ratio?

See our latest analysis for PerkinElmer How Do You Calculate PerkinElmer's P/E Ratio? … The formula for P/E is: Price to Earnings Ratio = Price per Share ÷ Earnings per Share (EPS) Or for PerkinElmer: P/E of 42.65 = $95.18 ÷ $2.23 (Based on the year to March 2019.) Is A High Price-to-Earnings Ratio Good? … A higher P/E ratio means that buyers have to pay a higher price for each $1 the company has earned over the last year.

Simply Wall St -

Is It Too Late To Buy PerkinElmer, Inc. (NYSE:PKI) At Its July Price?

PerkinElmer is trading at price-to-earnings (PE) ratio of 43.75x, this tells us the stock is overvalued compared to the US market average ratio of 18.24x , and overvalued based on current earnings compared to the Life Sciences industry average of 39.84x. … A PE ratio of 43.75x and expected year-on-year earnings growth of 20% give PerkinElmer a quite high PEG ratio of 2.23x. … So, when we include the growth factor in our analysis, PerkinElmer appears overvalued , based on the fundamentals.

Simply Wall St -

At US$93.38, Is It Time To Put PerkinElmer, Inc. (NYSE:PKI) On Your Watch List?

It’s trading around 15.64% above my intrinsic value, which means if you buy PerkinElmer today, you’d be paying a relatively fair price for it. … Since PerkinElmer’s share price is quite volatile, we could potentially see it sink lower (or rise higher) in the future, giving us another chance to buy. … PKI’s optimistic future growth appears to have been factored into the current share price, with shares trading around its fair value.

Simply Wall St -

Have Insiders Been Selling PerkinElmer, Inc. (NYSE:PKI) Shares?

So shareholders might well want to know whether insiders have been buying or selling shares in PerkinElmer, Inc. … As Peter Lynch said, 'insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.' View our latest analysis for PerkinElmer PerkinElmer Insider Transactions Over The Last Year The Independent Director, Patrick Sullivan, made the biggest insider sale in the last 12 months. … Insider Ownership of PerkinElmer Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own.

Simply Wall St -

Estimating The Fair Value Of PerkinElmer, Inc. (NYSE:PKI)

We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. … A DCF is all about the idea that a dollar in the future is less valuable than a dollar today, and so the sum of these future cash flows is then discounted to today's value: 10-year free cash flow (FCF) forecast 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 Levered FCF ($, Millions) $410.07 $472.61 $551.54 $615.60 $670.70 $718.21 $759.70 $796.65 $830.30 $861.64 Growth Rate Estimate Source Analyst x3 Analyst x3 Analyst x2 Est @ 11.62% Est @ 8.95% Est @ 7.08% Est @ 5.78% Est @ 4.86% Est @ 4.22% Est @ 3.78% Present Value ($, Millions) Discounted @ 9.45% $374.68 $394.55 $420.70 $429.04 $427.10 $417.88 $403.88 $386.97 $368.50 $349.41 Present Value of 10-year Cash Flow (PVCF)= $3.97b "Est" = FCF growth rate estimated by Simply Wall St The second stage is also known as Terminal Value, this is the business's cash flow after the first stage. … NYSE:PKI Intrinsic value, May 20th 2019 Important assumptions Now the most important inputs to a discounted cash flow are the discount rate, and of course, the actual cash flows.

Simply Wall St -

What does PerkinElmer, Inc.'s (NYSE:PKI) Balance Sheet Tell Us About Its Future?

the key to their continued success lies in its financial health. … This article will examine PerkinElmer’s financial liquidity and debt levels to get an idea of whether the company can deal with cyclical downturns and maintain funds to accommodate strategic spending for future growth. … Note that this commentary is very high-level and solely focused on financial health, so I suggest you dig deeper yourself

Simply Wall St -

Should We Be Cautious About PerkinElmer, Inc.'s (NYSE:PKI) ROE Of 9.2%?

While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it is important. … Our data shows PerkinElmer has a return on equity of 9.2% for the last year. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

Is PerkinElmer, Inc.'s (NYSE:PKI) High P/E Ratio A Problem For Investors?

We'll show how you can use PerkinElmer, Inc.'s (NYSE:PKI) P/E ratio to inform your assessment of the investment opportunity. … Looking at earnings over the last twelve months, PerkinElmer has a P/E ratio of 46.55. … Price to Earnings Ratio = Share Price ÷ Earnings per Share (EPS)

Simply Wall St -

Did Business Growth Power PerkinElmer's (NYSE:PKI) Share Price Gain of 117%?

But on the bright side, if you buy shares in a high quality company at the right price, you can gain well over 100%. … One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price. … This EPS growth is slower than the share price growth of 17% per year, over the same period.

Simply Wall St -

Will PerkinElmer, Inc.'s (NYSE:PKI) Earnings Grow Over The Next Year?

Based on PerkinElmer, Inc.'s (NYSE:PKI) earnings update on 30 December 2018, … it seems that analyst forecasts are fairly optimistic, … the past 5-year average growth rate of 1.0%.

Simply Wall St -

PKI Company Info

Description

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Details
Name: PerkinElmer, Inc.
PKI
Exchange: NYSE
Founded: 1937
$10,548,348,494
110,918,491
Website: http://www.perkinelmer.com
Address: PerkinElmer, Inc.
940 Winter Street,
Waltham,
Massachusetts, 02451,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NYSE PKI Common Stock New York Stock Exchange US USD 02. Jan 1968
DB PKN Common Stock Deutsche Boerse AG DE EUR 02. Jan 1968
LSE 0KHE Common Stock London Stock Exchange GB USD 02. Jan 1968
BMV PKI * Common Stock Bolsa Mexicana de Valores MX MXN 02. Jan 1968
Number of employees
Current staff
Staff numbers
12,500
PerkinElmer employees.
Industry
Life Sciences Tools and Services
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/17 23:45
End of day share price update: 2019/07/17 00:00
Last estimates confirmation: 2019/07/16
Last earnings filing: 2019/05/07
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.